Form 4: Adverum COO Reports Equity Changes Post-Eli Lilly Merger

Adverum Biotechnologies' COO, Peter Soparkar, reported the disposition of common stock, RSUs, PSUs, and stock options following the company's acquisition by Eli Lilly and Company.

Summary

• The merger of Adverum Biotechnologies, Inc. with Flying Tigers Acquisition Corporation, a direct wholly-owned subsidiary of Eli Lilly and Company, became effective on December 9, 2025.
• Peter Soparkar, Chief Operating Officer, disposed of 80,189 shares of common stock in connection with the merger.
• He also disposed of 13,125 Restricted Stock Units (RSUs) and 157,333 Performance Stock Units (PSUs) as part of the merger terms.
• Multiple stock options with exercise prices ranging from $4.20 to $10.14 were cancelled for no consideration at the effective time of the merger.
• Tendering stockholders received $3.56 per share in cash and one non-tradable Contingent Value Right (CVR) for each share.
• Holders of cancelled RSUs and PSUs also received an equivalent cash amount ($3.56 per share equivalent) and one CVR for each unit.
• CVRs represent the contractual right to receive up to two contingent cash payments, totaling up to an aggregate of $8.91 per CVR, upon the achievement of specified milestones.
• A grant of 150,000 Performance Stock Units (PSUs) approved on September 12, 2025, vested 100% upon the closing of the merger, prior to their disposition.

Sentiment

Score: 7

Explanation: The filing reflects the successful completion of a merger, providing shareholders with immediate cash and potential future upside via CVRs, which is generally positive for the acquired company's stakeholders, despite the cancellation of out-of-the-money options.

Positives

• The merger was successfully completed, providing immediate cash consideration of $3.56 per share to former Adverum Biotechnologies shareholders.
• Former shareholders, RSU holders, and PSU holders received Contingent Value Rights (CVRs) which offer potential additional cash payments up to an aggregate of $8.91 per CVR upon the achievement of specified milestones.
• A significant grant of 150,000 performance stock units vested 100% due to the change of control event (merger).

Negatives

• Out-of-the-money stock options, with exercise prices equal to or greater than the cash consideration, were cancelled for no consideration at the effective time of the merger.

Risks

• Contingent Value Rights (CVRs) are non-tradable and their payments are contingent upon the achievement of specified milestones, meaning future payments are not guaranteed and may not reach the maximum potential of $8.91 per CVR.

Future Outlook

The future outlook for former Adverum shareholders includes potential additional cash payments from Contingent Value Rights (CVRs) if specified milestones are achieved, up to an aggregate of $8.91 per CVR.

Industry Context

The acquisition of Adverum Biotechnologies by Eli Lilly and Company reflects a broader trend in the pharmaceutical and biotechnology industry where larger companies acquire smaller biotechs to expand their pipeline or gain access to specific therapeutic areas. The use of Contingent Value Rights (CVRs) is a common mechanism in such deals to bridge valuation gaps and share future risks/rewards related to clinical or regulatory milestones.

Comparison to Industry Standards

• The use of Contingent Value Rights (CVRs) in the merger consideration is a common practice in biotech acquisitions, particularly when the acquired company has pipeline assets with uncertain future value. This structure allows the acquirer to limit upfront cash outlay while providing former shareholders with upside potential tied to specific development or commercial milestones.
• Similar CVR structures have been observed in other significant biotech acquisitions, such as Celgene's acquisition by Bristol-Myers Squibb and Allergan's acquisition by AbbVie, where CVRs were utilized to incentivize future performance or mitigate risk associated with pipeline assets.

Stakeholder Impact

• Shareholders received $3.56 per share in cash and one Contingent Value Right (CVR) for each share, offering potential future payments.
• Holders of Restricted Stock Units (RSUs) and Performance Stock Units (PSUs) received equivalent cash and CVRs.
• Holders of out-of-the-money stock options had their options cancelled for no consideration.

Next Steps

• Achievement of specified milestones for Contingent Value Right (CVR) payments.

Key Dates

Keywords

Adverum Biotechnologies, ADVM, Eli Lilly, Merger, Acquisition, Form 4, Insider Transaction, Peter Soparkar, Contingent Value Right, CVR, Restricted Stock Units, Performance Stock Units, Stock Options